Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

Tinker, A.V ; Ellard, S ; Welch, S ; Moens, F ; Allo, G ; Tsao, M.S ; Squire, J ; Tu, D ; Eisenhauer, E.A ; MacKay, H

Gynecologic oncology, 2013-08, Vol.130 (2), p.269-274 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível